Bayer operates in three segments: Pharmaceuticals, Consumer Health and Crop Science – and the Animal Health business. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
The division also comprises the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents. The company recorded sales of €46.7 billion in 2016 an increase by 1.5% compared to €46.1 billion in 2015. The earnings per share in 2016 was €7.3. The pharmaceutical division sales €16.4 billion in 2016 an increase of 7% in comparison with 2015. This can be attributed to high combined growth of top five selling products recording a total combined sales of € 5.4 billion. The fiscal fourth quarter (Q4) sales were €11.8 billion, an increase of 5% compared to 2015 Q4 sales of €11.3 billion. The Q4 pharmaceutical sales was recorded at €4.3 billion, an increase of 7% compared to 2015 Q4 pharmaceuticals sales. This driving factor for high growth is successfully launched products Xarelto (Rivaroxaban), Eylea (aflibercept), Stivarga (regorafenib), Xofigo (radium Ra 223 dichloride) and Adempas (riociguat). In 2016, growth in the pharmaceuticals market weakened particularly in the United States, Europe and Japan. The pace of growth held steady in Asian and Latin American markets.
Strategic highlights: (Q4, 2016)
Founding member and Life Sciences partner of CUBE, a global start-up initiative headquartered in Berlin. (Oct)
Leica Biosystems for the development of companion diagnostic tests based on tissue samples using RNAscope and immunohistochemistry for cancer patients. (Dec)
Versant Ventures to the launch of BlueRock Therapeutics, a regenerative medicine company that plans to develop induced pluripotent stem cell therapies to cure a range of diseases using an industry-leading platform. (Dec)
Launched its clinical Phase III study with Nifurtimox in children of all age groups with Chagas disease, presented at the Annual Meeting of ASTMH. (Nov)
Announced results from the Phase IIIb PIONEER AF-PCI study, with its oral Factor Xa inhibitor Xarelto (rivaroxaban) for reducing the risk of bleeding in patients with non-valvular atrial fibrillation. (Nov)
Announced the submission to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for treatment of patients with hepatocellular carcinoma. (Nov)
Concluded the European registration procedure to gain EU-wide marketing authorization for its new low-dose levonorgestrel-releasing intrauterine system – Kyleena. (Oct)
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.